Diagnostics Solutions Strategic Priorities

SARS-CoV-2 diagnostics portfolio¹ Comprehensive portfolio of tests and digital solutions Clinical Labs • cobas® SARS-COV-2 • cobasⓇ SARS-CoV-2 Variant Molecular solutions cobasⓇ SARS-CoV-2 & Influenza A/B Immunology solutions TIB MOLBIOL LightMix® Modular SARS-CoV-2 Near Patient Launched Launched Launched • cobasⓇ SARS-CoV-2 & Influenza A/B Launched • cobas® SARS-CoV-2 Roche Launched In-development . ElecsysⓇ Anti-SARS-CoV-2 ElecsysⓇ Anti-SARS-CoV-2 S² ElecsysⓇ SARS-CoV-2 antigen Launched Launched Launched4 • SARS-CoV-2 rapid antibody • SARS-COV-2 rapid antigen Launched 3,4 Launched 3,4 SARS-CoV-2 rapid antigen nasal • ElecsysⓇ IL-6 Test to diagnose cytokine release syndrome Launched • SARS-CoV-2 rapid antigen nasal self-testing • SARS-COV-2 & Influenza A/B rapid antigen Launched 3,4 Launched 3,4,5 In-development3,4 • NAVIFY Remote Monitor6 Launched Digital solutions Viewics LabOps COVID-19 for efficiency improvements Launched • v-TAC digital algorithm for blood-gas Launched • iThemba Life COVID-19 Launched cobas Infinity POC COVID-19 Launched . NAVIFY Pass Launched CER: Constant Exchange Rates (avg FY 2020); 1 Not all products are available in all countries; 2 Spike protein; 3 External distribution partnership; 4 Not yet approved in the U.S; 5 Germany only; 6 US only; 7 v-TAC: venous to arterial conversion 24

View entire presentation